Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Can’t Be More Risky. Short Interest Increased

April 17, 2018 - By Linda Rogers

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Logo

Investors sentiment decreased to 1.03 in Q4 2017. Its down 0.14, from 1.17 in 2017Q3. It is negative, as 65 investors sold Alexion Pharmaceuticals, Inc. shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported.
State Of Wisconsin Inv Board holds 369,966 shares or 0.12% of its portfolio. Verity Asset Management has 0.24% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 2,626 shares. Cambridge Inv Research Advsr stated it has 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). The Sweden-based Livforsakringsbolaget Skandia Omsesidigt has invested 0.04% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 5,933 were accumulated by Kentucky Retirement Systems Insurance Fund. 3,245 were reported by Comerica Securities Inc. Moreover, University Of Notre Dame Du Lac has 1.77% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Employees Retirement Of Texas accumulated 106,000 shares. 2,000 were reported by Oakworth. 5,704 were reported by Cleararc Cap. The Switzerland-based Jabre Cap Partners has invested 0.87% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Ghost Tree Cap Ltd Liability Corp accumulated 3.23% or 115,000 shares. Kbc Nv holds 0.02% or 20,176 shares. Lazard Asset Mngmt Limited Com reported 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Amer Natl Registered Invest Advisor holds 0.19% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 3,340 shares.

Since January 2, 2018, it had 0 insider purchases, and 12 selling transactions for $4.62 million activity. HANTSON LUDWIG sold $310,521 worth of stock or 2,553 shares. $169,696 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Franchini Indrani Lall on Tuesday, February 6. The insider Moriarty John B sold $147,865. 655 shares valued at $76,805 were sold by Wagner Heidi L on Monday, February 5. The insider Goff Brian sold $192,028. 6,079 shares were sold by Clancy Paul J, worth $707,048 on Tuesday, February 6.

The stock of Alexion Pharmaceuticals Inc (NASDAQ:ALXN) registered an increase of 7.8% in short interest. ALXN’s total short interest was 4.50M shares in April as published by FINRA. Its up 7.8% from 4.17 million shares, reported previously. With 2.57 million shares average volume, it will take short sellers 2 days to cover their ALXN’s short positions. The short interest to Alexion Pharmaceuticals Inc’s float is 2.02%.

The stock increased 3.47% or $3.8 during the last trading session, reaching $113.28. About 1.63M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 17, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $25.19 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 57.5 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 14 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Alexion Pharmaceuticals had 26 analyst reports since October 20, 2017 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by BMO Capital Markets on Thursday, February 8. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, October 27. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Outperform” rating given on Thursday, January 4 by Raymond James. On Friday, February 9 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Nomura with “Buy” on Monday, March 19. The firm has “Buy” rating by BMO Capital Markets given on Friday, October 20. Leerink Swann maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Wednesday, December 6. Leerink Swann has “Buy” rating and $169.0 target. The stock has “Overweight” rating by PiperJaffray on Monday, October 23. The rating was reinitiated by Credit Suisse on Thursday, January 18 with “Outperform”. The stock has “Buy” rating by Stifel Nicolaus on Monday, October 23.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.